Evidence map›Paper›PMID 29189762›Full record

ArticleMolecules (Basel, Switzerland)2017

Synthesis and In Vitro Antimycobacterial Activity of Novel N-Arylpiperazines Containing an Ethane-1,2-diyl Connecting Chain.

Tomáš Goněc, Ivan Malík, Jozef Csöllei, Josef Jampílek, Jiřina Stolaříková, Ivan Solovič, Peter Mikuš, Stanislava Keltošová, Peter Kollár, Jim O'Mahony and 1 more

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Investigation of Hydro-Lipophilic Properties ofMolecules (Basel, Switzerland) · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tomáš GoněcDepartment of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences in Brno, Palackého 1946/1, Brno CZ-612 42, Czech Republic. gonect@vfu.cz.
Ivan MalíkDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University in Bratislava, Odbojárov 10, Bratislava SK-832 32, Slovakia. malikivan001@gmail.com.
Jozef CsölleiDepartment of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences in Brno, Palackého 1946/1, Brno CZ-612 42, Czech Republic. csolleij@vfu.cz.
Josef JampílekDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University in Bratislava, Odbojárov 10, Bratislava SK-832 32, Slovakia. josef.jampilek@gmail.com.ORCID 0000-0003-2003-9052
Jiřina StolaříkováLaboratory for Mycobacterial Diagnostics and Tuberculosis, Regional Institute of Public Health, Partyzánské náměstí 7, Ostrava CZ-702 00, Czech Republic. Jirina.Stolarikova@zu.cz.
Ivan SolovičClinic for Tuberculosis and Lung Diseases, National Institute for Tuberculosis, Lung Diseases and Thoracic Surgery, Vyšné Hágy, Vysoké Tatry SK-059 84, Slovakia. solovic@hagy.sk.
Peter MikušDepartment of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava, Odbojárov 10, Bratislava SK-832 32, Slovakia. mikus@fpharm.uniba.sk.
Stanislava KeltošováDepartment of Human Pharmacology and Toxicology, University of Veterinary and Pharmaceutical Sciences in Brno, Palackého 1946/1, Brno CZ-612 42, Slovakia. keltosovas@vfu.cz.
Peter KollárDepartment of Human Pharmacology and Toxicology, University of Veterinary and Pharmaceutical Sciences in Brno, Palackého 1946/1, Brno CZ-612 42, Slovakia. kollarp@vfu.cz.
Jim O'MahonyDepartment of Biological Sciences, Cork Institute of Technology, Bishopstown, Cork T12 P928, UK. jim.omahony@cit.ie.
Aidan CoffeyDepartment of Biological Sciences, Cork Institute of Technology, Bishopstown, Cork T12 P928, UK. aidan.coffey@cit.ie.ORCID 0000-0003-4116-9913

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel 1-(2-{3-/4-[(alkoxycarbonyl)amino]phenyl}-2-hydroxyethyl)-4-(2-fluorophenyl)-piperazin-1-ium chlorides (alkoxy = methoxy to butoxy;

Indexed as

Antitubercular AgentsCell Line, TumorCell SurvivalHumansHydrophobic and Hydrophilic InteractionsMicrobial Sensitivity TestsMolecular StructureMycobacterium tuberculosisPiperazinesSpectrum AnalysisStructure-Activity RelationshipAntitubercular AgentsPiperazinesarylaminoethanolselectronic propertieslipophilicityMycobacterium tuberculosis H37RvN-arylpiperazines

Identifiers

PMID29189762
PMCPMC6149664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.